|
1) Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008; 123: 8-13
|
|
|
|
2) Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20: 2429-40
|
|
|
|
|
|
3) Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al, for the International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10: 223-32
|
|
|
|
|
|
4) Uchida T, Ogawa Y, Kobayashi Y, et al. Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Sci. 2011; 102: 432-8
|
|
|
|
|
5) Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2010; 85: 130-8
|
|
|
|
|
|
6) Götze K, Platzbecker U, Giagounidis A, et al. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Ann Hematol. 2010; 89: 841-50
|
|
|
|
|
|
7) Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106: 1794-803
|
|
|
|
|
|
8) Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011; 29: 1987-96
|
|
|
|
|
|
9) Silverman LR, Verma A, Odchimar-Reissig R, et al. A Phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium. J Clin Oncol. 2008; 26: (May 20 supple; abstr 7000)
|
|
|
|
|
|
10) Gore SD, Sun Z, Greenberg PL, et al. Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplasitc syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the US Leukemia Intergroup Trial E1905. Blood. 2010; 116: abstr#601
|
|
|
|
|
|
11) Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol. 2010; 28: 2253-8
|
|
|
|
|
|
12) de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010; 116: 5420-31
|
|
|
|
|
|
13) Kim DY, Lee JH, Park YH, et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant. 2011 Apr 11. [Epub ahead of print] PMID: 21478916
|
|
|
|
|